Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
131 Leser
Artikel bewerten:
(0)

Conversa's Advanced Automated Patient Engagement Platform Earns Industry Leadership Recognition from Frost & Sullivan

Conversa leads market powering a continuous, collaborative, and efficient provider-patient relationship

SANTA CLARA, California, Sept. 18, 2018 /PRNewswire/ -- Based on its recent analysis of the North American patient engagement solutions market, Frost & Sullivan recognizes Conversa Health (Conversa) with the 2018 North American Technology Leadership Award for filling the gaps in traditional care through its automated, artificial intelligence (AI)-based Conversa Conversation Platform. This consumer-centric platform optimizes patient engagement, care team satisfaction, and clinical and financial outcomes through targeted patient outreach and coordinated care management.

Photo - https://mma.prnewswire.com/media/741363/Conversa_Health_Award.jpg

"Conversa is delivering better patient access and virtual care with its profile-driven, automated health conversations. Their cloud-based technology enhances care management and clinical understanding through deep integration with more than 400 biometric devices as well as patients' electronic health records (EHRs)," said Koustav Chatterjee, Industry Analyst, Frost and Sullivan. "Its secure and reliable conversational AI technology easily syncs with a patient portal, EHR, or client app and captures actionable data through chats that are sophisticated, empathetic, and easy to analyze."

Clients use Conversa in a range of applications including chronic condition management, pre- and post-surgery, medication adherence, patient acquisition/retention and lifestyle health coaching. This allows caregivers to offer educational content and insights to foster an understanding of disease processes and reduce patient anxiety. Additionally, Conversa uniquely employs a proven motivational psychology methodology, wherein self-determination and superior patient-generated health data (PGHD) integration supports personalized conversational experiences and spurs patient engagement.

Conversa's structured approach further ensures high data integrity and minimizes escalations. In fact, it has a library of more than 500 conversation programs addressing conditions such as asthma, chronic obstructive pulmonary disease, and hypertension; this branching logic and structured data helps it present an easy-to-use client interface. In addition, the solution delivers a gamification feature to interact with patients, and providers can even adjust the literacy level and language according to their patient's needs.

"Conversa's primary customers include healthcare systems, pharmaceuticals, payers, and technology companies. Conversa's significant performance has demonstrated value for its clients and has attracted significant support from a syndicate of top healthcare investors such as Northwell Health, Triple Tree, Allscripts, and Epic Ventures," noted Koustav. "Overall, Conversa's proven outcomes, ease-of-use, and visionary innovation have resulted in best-in-class patient engagement, remote in-home monitoring, and significant clinical and financial outcomes for its clients, catapulting the company into the market leadership position."

"We're very honored to be featured in this market report and receive this prestigious award from Frost and Sullivan, one the industry's top research organizations," said West Shell III, Conversa's CEO and co-founder. "Along with this industry leadership award, our growing client base is evidence that Conversa's proven solution is standing out from the crowd as we help our clients monitor and manage patient populations at scale more efficiently than they ever have before."

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient's technology. To view the Frost and Sullivan analyst speaking about this award, click here.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Samantha Park
P: 210.247.2426
F: 210.348.1003
E: samantha.park@frost.com

About Conversa Health
As healthcare's conversation platform, Conversa delivers an easy and meaningful way for care teams and patients to communicate. Conversa has an extensive library of over 500 clinically-intelligent conversation programs that include asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension, joint replacement, and many more. Using Conversa's innovative and scalable Conversational AI technology, healthcare organizations can deliver automated, personalized doctor-patient conversation experiences that lead to more informed and meaningful patient relationships, effective population management, and, ultimately, better clinical and financial outcomes. For more information, visit conversahealth.com

Contact:
Chris Edwards
P: 919.260.2231
E: chris.edwards@conversahealth.com

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.